Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon's first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types. HD-001 modulates a novel kinase, which is mutated in multiple cancer types including lung and colon tumours. What is more, the target seems to be crucial in cells with K-RAS mutations, which have been found in 40% of all cancers that have become resistant to available therapeutics.
The companies said that the preclinical programme have the potential for a blockbuster drugs as K-RAS defective cells are currently not druggable. Under the terms of the agreement, Horizon will receive undisclosed upfront and preclinical milestone payments, and are eligible for clinical and approval milestones totalling up to US$75m, as well as tiered royalties.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.